NASDAQ: CASI | 中文 | Contact Us

Clinical Trials

Post-Market Study in China

Drug Indication Topic
Evomela (melphalan) For Injection Multiple Melanoma To evaluate the efficacy and safety of Evomela for maintenance treatment of Multiple Melanoma

Upcoming Clinical Trials

Drug Indication Topic
CID-103 Multiple Melanoma To evaluate the efficacy and safety of CID-103 for treatment of Multiple Melanoma


For more information on trials conducted by our partners for CNCT19 and BI-1206, please refer to clinicaltrials.gov.

About Us

CASI is a U.S. NASDAQ-listed biopharmaceutical company with a platform to develop and accelerate the launch of pharmaceutical products and innovative therapeutics in China, the U.S., and throughout the world. We have offices in Rockville, Maryland, and a wholly owned subsidiary in Beijing, China, through which substantially all of our operations are conducted.

Learn More